It has been almost three months since the coronavirus-driven volatility hit the global economy, and the market continues to rapidly move into both …
Yesterday, the FDA approved Verastem’s (VSTM) lead product, Copiktra (duvelisib), as the first PI3K-δ/-γ inhibitor for the treatment of third-line chronic lympocytic leukemia (CLL), small …
Yesterday, Verastem (VSTM) announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in …
Hedge fund manager Mitchell J. Blutt of the $1.
Verastem (NASDAQ:VSTM) just riled up Wall Street today with enticing Phase Ib/II study results in chronic lymphocytic leukemia (CLL), sending shares on a …
Shares of Verastem Oncology (NASDAQ:VSTM) are up nearly 15% as of 12:04 p.m.
By Harriet Lefton You don’t need to spend big to pick up premium stock picks… not when you can use the markets’ current …
FBR’s George Zavoico believes strong data for Verastem’s lead drug candidate duvelisib helped impress Japan’s Yakult Honsha.
Roth Capital analyst Joseph Pantginis assigned a Buy rating on Verastem (NASDAQ:VSTM) with a $29 price target, which represents a potential upside of 188% …
